Panc02-Luc Cells

Panc02-Luc is a luciferase-expressing derivative of the Panc02 murine pancreatic adenocarcinoma cell line. Panc02 cells originate from chemically induced pancreatic ductal adenocarcinoma in mice and are widely used as a syngeneic model of pancreatic cancer in immunocompetent murine hosts. The introduction of a luciferase reporter enables highly sensitive bioluminescent imaging of tumor cells in vitro and in vivo, facilitating noninvasive longitudinal monitoring of tumor growth, metastatic dissemination, and therapeutic response. These properties make Panc02-Luc a valuable platform for pancreatic cancer biology, immuno-oncology, and preclinical drug development studies.

Panc02-Luc cells are commonly utilized in orthotopic and subcutaneous mouse tumor models to investigate tumor progression, stromal interactions, immune cell infiltration, and mechanisms of resistance to chemotherapy or immunotherapy. Because Panc02 tumors can be established in syngeneic mouse strains with an intact immune system, the model is particularly useful for evaluating checkpoint inhibitors, adoptive cell therapies, cancer vaccines, and combination treatment strategies. Luciferase-based imaging enables repeated quantitative assessment of tumor burden in living animals, reducing experimental variability and supporting real-time evaluation of treatment efficacy.

Panc02-Luc cells are used for studies of pancreatic tumor cell proliferation, migration, invasion, cytokine signaling, metabolic adaptation, and apoptosis. The biological behavior of the model may vary depending on the luciferase construct, promoter system, and clonal selection strategy used during engineering. Further characterization data, including reporter stability, luminescence intensity, and metastatic potential, may be important for specialized experimental applications.